ELTX (Elicio Therapeutics) Institutional Ownership: 16.47% (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTX Elicio Therapeutics Inc ELTX
28 GF Score
Price $3.17
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics Institutional Ownership?

Elicio Therapeutics ELTX +0.96% 28 Institutional Ownership is 16.47% as of Jul. 23, 2026. GuruFocus rates ELTX with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Elicio Therapeutics's institutional ownership is 16.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Elicio Therapeutics's Insider Ownership is 2.19%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Elicio Therapeutics's Float Percentage Of Total Shares Outstanding is 77.61%.

Elicio Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Institutional Ownership Chart

Elicio Therapeutics Historical Data

The historical data trend for Elicio Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.20 5.42 6.33 5.67 6.28 7.69 7.79 7.75 8.00 12.09
ELTX
28GF Score
Elicio Therapeutics Inc ELTX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 16.47% mean?
Elicio Therapeutics (ELTX) has a Institutional Ownership of 16.47% as of Jul. 23, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Institutional Ownership too high?
Elicio Therapeutics' current Institutional Ownership is 16.47%. Overall, Elicio Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Institutional Ownership compare to GOSS and GANX?
Elicio Therapeutics' Institutional Ownership of 16.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current Institutional Ownership is 16.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Institutional Ownership of 16.47%. The current Institutional Ownership is 16.47%. Elicio Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Institutional Ownership is 16.47% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
28GF Score

Get the complete analysis for ELTX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.17
Price